A new study by Mayo Clinic Comprehensive Cancer Center researchers found that the presence of a specific genetic ...

PanCAN Chief Scientific & Medical Officer Dr. Anna Berkenblit writes about the critical federal funding at risk and what this ...

PDAC, an aggressive and often difficult-to-diagnose cancer, frequently spreads before detection. The study, published in the ...

The trial’s first phase will begin in university hospitals across the Netherlands, Denmark, Germany and Sweden.

Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer-related mortality worldwide. Current treatment modalities are few or ...

A new study from Memorial Sloan Kettering Cancer Center has shown that an RNA-based neoantigen vaccine can generate ...

Encouraging preclinical data supporting the use of DNase-based technology to target NETosis and address difficult to treat cancersStrategic focus ...

The study demonstrates that PAC-MANN-1 outperforms the widely used CA 19-9 biomarker, offering greater accuracy in detecting all stages of PDAC. The assay is particularly promising for identifying ...

Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, today announced positive results from the VERIFI study, the second clinical validation study of its next-generation ...

A novel, rapid blood test demonstrated potential for detecting early-stage pancreatic cancer, according to results of a ...

CTA approval marks Anocca’s transition to a clinical-stage companyFirst-in-human VIDAR-1 trial begins with the deployment of ANOC-001 in Advanced ...

Adding immunotherapy to new KRAS inhibitors boosted responses in preclinical models, setting the stage for future trials of the combination strategy.